Cellectar Biosciences, Inc..
CLRB.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of proprietary drugs for the treatment of cancer. The company's product pipeline is built upon its proprietary phospholipid drug conjugate (PDC) delivery platfo...Show More
Better Health for All
0
Cellectar Biosciences' core business is entirely focused on developing targeted cancer drugs, with its lead product candidate, iopofosine I 131, showing promising clinical efficacy. In pediatric high-grade glioma, it demonstrated extended progression-free survival (average 5.4 months vs. 2.25 months in literature) and overall survival (average 8.6 months vs. 5.6 months in literature).
1
For recurrent head and neck cancer, an investigator-initiated Phase 1 study reported a 64% complete remission rate and 73% overall response rate.
2
The drug has a favorable safety profile, with predictable and manageable hematologic adverse events and no cardiovascular, renal, liver, or neurological toxicities reported.
3
The company's clinical trials include vulnerable populations such as children, adolescents, and young adults with high-grade glioma.
4
However, the company has secured four patent grants in Europe, Australia, and Canada for its PDC delivery platform and iopofosine I 131, with no evidence of patent flexibility for global health needs.
5
While safety data and adverse events are reported, there is no comprehensive information on risk transparency or public health information. The company is actively conducting clinical trials across multiple sites in the US and Canada, evaluating safety, tolerability, and therapeutic activity.
6
Fair Money & Economic Opportunity
0
Cellectar Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer treatments.
1
The company's core business does not involve lending, insuring, moving, or storing money for consumers.
2
Therefore, all KPIs related to financial products, services, and their impact on economic opportunity for underserved populations are not applicable. There is no evidence of the company engaging in activities that would generate data for APRs, fees, loan books, customer financial data, or debt products.
3
Fair Pay & Worker Respect
0
No specific, concrete data points for any of the Fair Pay & Worker Respect KPIs for Cellectar Biosciences, Inc. (CLRB.US) were found in the provided articles. The articles primarily contain financial market data
1
or general industry survey results,
2
none of which are attributable to the company's specific practices regarding employee compensation, working conditions, or human rights.
Fair Trade & Ethical Sourcing
0
No evidence was found in the provided article to assess Cellectar Biosciences, Inc. against any of the Fair Trade & Ethical Sourcing KPIs.
1
The article discusses general industry initiatives for conflict-free sourcing but does not contain specific data or practices related to CLRB.US.
2
Honest & Fair Business
0
No evidence available to assess Cellectar Biosciences, Inc. on Honest & Fair Business.
Kind to Animals
-70
The company is not certified cruelty-free.
1
It conducts animal testing for its medical products, services, research, and therapies.
2
Drug candidates CLR 121225 and CLR 121125 were tested in multiple solid tumor animal models, including pancreatic, colorectal, breast cancer, and triple-negative breast cancer.
3
The safety and efficacy evaluation for CLR 1603-PTX is also conducted in animal tumor models.
4
There is no mention of a formal animal testing policy, restrictions, or oversight.
No War, No Weapons
0
No evidence available to assess Cellectar Biosciences, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Cellectar Biosciences, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Cellectar Biosciences, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company has not identified any material cybersecurity threats or intrusions that have affected its strategy, results, or financial condition, though it acknowledges being a target of cybersecurity threats.
1
It provides ongoing education communications on cyber and information security and monitors phishing campaigns to identify employees who might need additional training.
2
The company prohibits the unauthorized use or distribution of proprietary information, including customer data.
3
It conducts regular information technology risk evaluations and security audits with the assistance of third-party vendors and performs due diligence on key technology vendors.
4
The Board of Directors, with the Audit Committee's assistance, oversees risk management, including cybersecurity.
5
The company's Code of Ethics, adopted March 21, 2006, and revised November 7, 2022, emphasizes compliance with laws, rules, and regulations, including the U.S. Foreign Corrupt Practices Act and Sarbanes-Oxley Act.
6
It requires honest and accurate record-keeping and reporting, with a minimum retention period of five years for documentation related to complaints.
7
The company's website privacy policy states that users can set their browser to refuse cookies and that the site uses cookies to save passwords.
8
It also stores IP addresses as partial identifiers.
9
Zero Waste & Sustainable Products
0
No explicit data on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education is provided in the available articles.
1